Middle East Pharmaceutical Industries Company
4016.SRSAUHealthcare● Active
$62.10
$-0.20(-0.32%)
Market Cap$2.2B
P/E Ratio—
52W High$79.08572
52W Low$53.88572
Middle East Pharmaceutical Industries Company (4016.SR) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · 4016.SR · as of 2026-06-15
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.46B | $0.39B | $0.34B | $0.30B | $0.29B |
| Cost of Revenue | $0.17B | $0.15B | $0.13B | $0.12B | $0.12B |
| Gross Profit | $0.29B | $0.24B | $0.21B | $0.18B | $0.17B |
| Gross Margin %(computed) | 62.29% | 61.77% | 61.18% | 58.70% | 58.92% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.03B | $0.02B | $0.05B | $0.04B | $0.03B |
| Total Operating Expenses | $0.18B | $0.15B | $0.13B | $0.11B | $0.09B |
| Operating Income | $0.11B | $0.09B | $0.08B | $0.07B | $0.08B |
| Operating Margin %(computed) | 23.54% | 23.11% | 23.12% | 23.24% | 26.64% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.01B | $0.01B | $0.00B |
| Income Before Tax | $0.10B | $0.09B | $0.07B | $0.07B | $0.07B |
| Income Tax Expense | $0.01B | $0.01B | $0.01B | $0.01B | $0.00B |
| Net Income | $0.10B | $0.08B | $0.07B | $0.06B | $0.07B |
| Net Margin %(computed) | 21.07% | 20.27% | 19.45% | 19.64% | 23.08% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $2.77 | $2.28 | $1.88 | $1.70 | $1.89 |
| Wtd Avg Shares | 0.04B | 0.04B | 0.04B | 0.04B | 0.04B |
| EBITDA | $0.11B | $0.11B | $0.09B | $0.08B | $0.08B |
| EBITDA Margin %(computed) | 23.54% | 27.12% | 25.16% | 26.80% | 28.89% |
Data source: Financial Modeling Prep · Last updated: 2026-06-15 · SAR · B
Explore more Middle East Pharmaceutical Industries Company data
About Middle East Pharmaceutical Industries Company (4016.SR) Income Statement
Middle East Pharmaceutical Industries Company (4016.SR) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, 4016.SR reported revenue of $0.46B, gross profit of $0.29B (gross margin 62.29%), and net income of $0.10B — a net profit margin of 21.07%.
Frequently asked questions
4016.SR · 4 questionsMiddle East Pharmaceutical Industries Company (4016.SR) reported revenue of $0.46B for 2025, up 16.9% year-over-year.
4016.SR revenue4016.SR salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-15